Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
IRLAB Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 2/6
IRLAB Therapeutics is forecast to grow earnings and revenue by 47.1% and 47.3% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be 15.4% in 3 years.
Anahtar bilgiler
47.1%
Kazanç büyüme oranı
22.8%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 65.0% |
| Gelir büyüme oranı | 47.3% |
| Gelecekteki özkaynak getirisi | 15.4% |
| Analist kapsamı | Low |
| Son güncelleme | 05 Sep 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?
Jun 06
Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25
Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 89 | -116 | -116 | -116 | 1 |
| 12/31/2025 | 238 | 35 | 159 | 159 | 3 |
| 12/31/2024 | 121 | -92 | -17 | -17 | 3 |
| 6/30/2024 | 42 | -119 | -109 | -109 | N/A |
| 3/31/2024 | 6 | -157 | -162 | -162 | N/A |
| 12/31/2023 | 6 | -178 | -165 | -165 | N/A |
| 9/30/2023 | 19 | -176 | -169 | -169 | N/A |
| 6/30/2023 | 36 | -162 | -163 | -160 | N/A |
| 3/31/2023 | 52 | -144 | -155 | -151 | N/A |
| 12/31/2022 | 61 | -113 | -146 | -143 | N/A |
| 9/30/2022 | 61 | -103 | -136 | -133 | N/A |
| 6/30/2022 | 240 | 42 | 96 | 98 | N/A |
| 3/31/2022 | 217 | 43 | 117 | 118 | N/A |
| 12/31/2021 | 208 | 52 | 128 | 129 | N/A |
| 9/30/2021 | 196 | 55 | 140 | 141 | N/A |
| 6/30/2021 | 0 | -93 | -93 | -92 | N/A |
| 3/31/2021 | N/A | -93 | -88 | -87 | N/A |
| 12/31/2020 | 0 | -92 | -90 | -89 | N/A |
| 9/30/2020 | 0 | -99 | -99 | -99 | N/A |
| 6/30/2020 | 0 | -93 | -93 | -92 | N/A |
| 3/31/2020 | 1 | -98 | -98 | -98 | N/A |
| 12/31/2019 | 0 | -96 | -91 | -91 | N/A |
| 9/30/2019 | 1 | -88 | -83 | -83 | N/A |
| 6/30/2019 | 1 | -83 | -78 | -78 | N/A |
| 3/31/2019 | 0 | -76 | -75 | -75 | N/A |
| 12/31/2018 | 0 | -74 | -72 | -71 | N/A |
| 9/30/2018 | 0 | -68 | -76 | -75 | N/A |
| 6/30/2018 | 0 | -73 | -68 | -67 | N/A |
| 3/31/2018 | 0 | -60 | N/A | -58 | N/A |
| 12/31/2017 | 0 | -56 | N/A | -58 | N/A |
| 9/30/2017 | 0 | -58 | N/A | -48 | N/A |
| 6/30/2017 | 0 | -48 | N/A | -45 | N/A |
| 3/31/2017 | 3 | -44 | N/A | -45 | N/A |
| 12/31/2016 | 3 | -43 | N/A | -41 | N/A |
| 12/31/2015 | 3 | -12 | N/A | -28 | N/A |
| 12/31/2014 | 3 | 3 | N/A | -11 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: IRLAB A is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: IRLAB A is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: IRLAB A is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: IRLAB A's revenue (47.3% per year) is forecast to grow faster than the Swedish market (0.9% per year).
Yüksek Büyüme Geliri: IRLAB A's revenue (47.3% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: IRLAB A's Return on Equity is forecast to be low in 3 years time (15.4%).